Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 second-line axitinib study in advanced hepatocellular carcinoma after sorafenib
2011-002029-24Phase 2Active
- Sponsor
- Università Campus Bio-Medico di Roma
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axitinib in hepatocellular carcinoma (HCC), sponsored by Università Campus Bio-Medico di Roma. Primary endpoint: Rate of patients without progression. Started Sep 2012; status: active.
02
Drugs
axitinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2011-002029-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002029-24.